Gilead Signs US$1.7 B Deal with MacroGenics for Bispecific Antibodies

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)

Published: 20 Oct-2022

DOI: 10.3833/pdr.v2022.i10.2737     ISSN: 1756-7874

Section: Research & Development



In an attempt to strengthen its immuno-oncology pipeline, Gilead Sciences has entered into a collaboration agreement with MacroGenics to develop bispecific antibodies...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details